1. Taiwan Stocks

  2. •

    Technology services

  3. •

    Information technology services
Lytone Enterprise, Inc.

Lytone Enterprise, Inc.

TTPEX:1293
24.05
TWD
0.00
(0.00%)
461.54MMarket Cap
Lytone Enterprise, Inc.
TPEX:1293
(Taipei Exchange)

Recent

price

24.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
35.02
30.49
27.98
29.2
31.12
35.03
39.7
44.65
- -
Revenue per Share
0.42
-0.59
2.84
2.29
1.88
1.68
2.16
2.21
- -
Basic EPS, GAAP
0.61
0.56
2.05
1.86
0.8
4.25
1.34
0.42
- -
Free Cash Flow per Basic Share
- -
0.23
0.04
0.75
0.21
0.67
1
1.3
- -
Dividend per Share
5.24
4.71
7.21
10.33
12.25
13.17
14.5
15.4
14.52
Book Value per Share
4.04
3.66
6.18
9.47
11.56
12.72
14.1
14.75
13.91
Tangible Book Value per Share
9
9
15
16
17
17
17
17
17
Basic Weighted Avg Shares
330
287
426
467
532
599
679
763
- -
Sales/Revenue/Turnover
3.83
-2.18
10.67
9.26
7.68
7.07
5.57
6.22
- -
Operating Margin (%)
7
13
12
14
15
16
16
15
- -
Depreciation Expense
4
-6
43
37
32
29
37
38
- -
Net Income, GAAP
62.46
- -
9.89
18.81
24.24
30.54
22.19
25.01
- -
Effective Tax Rate (%)
1.21
-1.95
10.16
7.84
6.04
4.79
5.44
4.96
- -
Profit Margin (%)
47
28
75
125
161
225
226
228
198
Working Capital
18
19
19
10
15
68
57
41
35
LT Debt
91
82
126
180
209
225
248
263
248
Total Equity
- -
- -
24.77
17.02
12.49
10.03
8.96
10.02
- -
Return on Invested Capital (%)
- -
- -
27.29
18.79
14.12
10.52
11.97
11.29
- -
Return on Capital (%)
- -
-6.45
41.72
23.97
16.51
13.2
15.62
14.81
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
32
60
79
LT Borrowings
50
37
24
LT Finance Leases
5
4
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
505
489
462

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
373
437
449
Cash, Cash Equivalents & STI
127
163
115
Accounts Receivable, Net
93
108
77
Inventories
129
145
177
Total Current Liabilities
161
210
251
Payables & Accruals
- -
- -
- -
ST Debt
32
60
79
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
16.7%
6.21%
Free Cash Flow
- -
47.09%
-68.62%
Net Income, GAAP
- -
-1.43%
2.49%
Sales/Revenue/Turnover
- -
12.38%
12.48%
Total Cash Common Dividend
- -
400.19%
30%

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
679
2025
- -
- -
763
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2.16
2025
- -
- -
2.21
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
1.3
2026
- -
- -
- -
Similar Companies
Credo Technology Group Holding Ltd (NASDAQ:CRDO)
International Business Machines Corporation (NYSE:IBM)
Tata Consultancy Services Limited (NSE:TCS)
Infosys Limited (NSE:INFY)
HCL Technologies Limited (NSE:HCLTECH)
Cloudflare, Inc. (NYSE:NET)
Business
Lytone Enterprise, Inc. (1293.TWO) engages in the research, design, development, and commercialization of functional food products, animal husbandry biotechnology solutions, and agricultural biotechnology products in Taiwan. Founded in 1994 by William T.H. Chang Ph.D. and headquartered in Xizhi District, New Taipei City, Taiwan, the company offers post-harvest preservation techniques such as LytoFresh protocols and AnsiP-Sticker; functional fertilizers; livestock feed additives including immune stimulators, growth promoters, and health improvement products; food ingredients comprising plant extracts, animal tissue extracts, probiotics like patented Lactobacillus paracasei LT12, and branded formulations such as Stanxin and Lytodark; and healthy foods targeting metabolic syndrome improvements, skin and hair care, neuroprotection, gastrointestinal care, and allergy relief. It provides OEM/ODM services, CDMO capabilities for functional food formulas, and eco-friendly agriculture and livestock novelty solutions, serving growers, packers, retailers, and end customers globally. Operations span Taiwan, China via subsidiary Shanghai Lytone Biochemicals Ltd., Europe, the United States, Japan, Korea, Southeast Asia, New Zealand, Australia, and East Africa. Recent developments include the debut of patented strain LT12's multifunctional uric acid-lowering research results at the 19th International Symposium on Probiotics and Health in May 2024; a strategic partnership with Ming Chyi Biotechnology Ltd. in November 2022 to advance globalized probiotic services; receipt of the 2022 Taiwan BIO Award for Emerging Company of the Year; and listing on the Taipei Exchange Emerging Stock Market following its initial public offering under stock code 1293.